聚焦伯恩斯坦_中国GLP-1:ADA更新巩固850亿元总可市场容量。among China-based programs. The small molecule delivered 4-week placebo-adjusted weight loss of 8.6% in its first-in-human Ph1. This is one of the most potent early-phase oral readouts globally (best orals approved today give 8-11% weight loss at 60-70 weeks).
聚焦伯恩斯坦_中国GLP-1:ADA更新巩固850亿元总可市场容量。among China-based programs. The small molecule delivered 4-week placebo-adjusted weight loss of 8.6% in its first-in-human Ph1. This is one of the most potent early-phase oral readouts globally (best orals approved today give 8-11% weight loss at 60-70 weeks).
聚焦伯恩斯坦_中国GLP-1:ADA更新巩固850亿元总可市场容量。among China-based programs. The small molecule delivered 4-week placebo-adjusted weight loss of 8.6% in its first-in-human Ph1. This is one of the most potent early-phase oral readouts globally (best orals approved today give 8-11% weight loss at 60-70 weeks).
覆盖 2026 年,全文约 24。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
重点分析了伯恩斯坦_中国GLP等议题。